SOURCE-LINKED STUDY SUMMARY
Bimagrumab improves body composition and insulin sensitivity in insulin-resistant individuals.
Abstract summarizedQuality not appraised
- What was studied
- This placebo-controlled experiment tested whether bimagrumab-induced body-composition changes could improve insulin sensitivity in people with insulin resistance.
- Who / model studied
- Sixteen participants had insulin resistance and a mean body-mass index of 29.3 kg/m².
- Studied dose & schedule
- Participants received one dose of bimagrumab or placebo. Body composition and insulin sensitivity were assessed at week 10; the abstract did not report dose or route.
- What the study found
- Versus placebo, bimagrumab increased lean mass 2.7% and reduced fat mass 7.9% at week 10 without changing body weight. Insulin sensitivity improved about 20% by clamp and 40% by IVGTT.
- Limitations & context
- The sample was very small, exposure was a single dose, and the abstract omitted dose, route and adverse-event detail. Different insulin-sensitivity methods produced different estimates.
Read summary source ↗ · Prepared 10/6/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1111/dom.13042